Abstract:Background Metabolic dysfunction-associated steatotic liver disease (MASLD) imposes a substantial global disease burden. This study aims to elucidate the role of intestinal NOD-like receptor thermal protein domain associated protein 3 (NLRP3) inflammasome in the gut-liver axis and provide novel insights for potential therapeutic targets. Methods Mice were fed with a methionine-choline deficient (MCD) diet for four weeks to induce MASLD models. Nlrp3fl/fl and Vil1creNlrp3fl/fl mice, with a specific knockout of NLRP3 in intestinal epithelial cells, were housed either separately or together to establish models for MASLD. Liver and intestinal tissues were collected for the assessment of hepatic steatosis, inflammation, fibrosis, and integrity of the intestinal mucosal barrier, while fecal microbiota composition was analyzed using 16S rDNA sequencing. The in vivo effects of intragastric butyrate were evaluated using Vil1creNlrp3fl/fl-MCD mice. Results Wild-type (WT)-MCD mice exhibited exacerbated hepatic steatosis and reduced intestinal NLRP3 mRNA expression compared to WT mice fed with a methionine-choline sufficient (MCS) diet, suggesting a protective role of intestinal NLRP3. The Vil1creNlrp3fl/fl-MCD vs. Nlrp3fl/fl-MCD mice exhibited elevated hepatic lipid deposition and increased expression of α-SMA. Additionally, they displayed compromised intestinal mucosal barrier function characterized by shortened villi, reduced goblet cell count, and decreased expression of Reg3a and Cldn7. The co-housed Vil1creNlrp3fl/fl-MCD with Nlrp3fl/fl-MCD mice showed a significantly ameliorated liver phenotype, characterized by reduced steatosis and fibrosis, in comparison with separately-housed Vil1creNlrp3fl/fl-MCD mice. This improvement was accompanied by an increased abundance of Faecalibaculum rodentium, a well-known butyrate producer. The in vivo administration of butyrate significantly ameliorated hepatic lipid accumulation and fibrogenesis in Vil1creNlrp3fl/fl-MCD mice. Further, a significant upregulation of activating protein-1 (AP-1) mRNA levels was observed in the liver of Vil1creNlrp3fl/fl-MCD mice, while both co-housed Vil1creNlrp3fl/fl-MCD mice and butyrate administration significantly exhibited downregulated expression of AP-1. Conclusions Deletion of NLRP3 in intestinal epithelial cells leads to a reduction in the abundance of Faecalibaculum rodentium and butyrate production, resulting in the upregulation of hepatic AP-1 expression, thereby exacerbating MASLD.

Metabolic dysfunction-associated steatotic liver disease exhibits sex-specific microbial heterogeneity within intestinal compartments

Sex-Dependent Gut Microbiota Features and Functional Signatures in Metabolic Disfunction-Associated Steatotic Liver Disease

Sex- and age-associated factors drive the pathophysiology of MASLD

Gender Differences in Bile Acids and Microbiota in Relationship with Gender Dissimilarity in Steatosis Induced by Diet and FXR Inactivation

Manipulating the Gut Microbiome to Alleviate Steatotic Liver Disease: Current Progress and Challenges

Cross talk between the liver microbiome and epigenome in patients with metabolic dysfunction-associated steatotic liver disease

HIGH-FAT DIET ELICITS SEX-BASED DIFFERENCES IN LIVER INFLAMMATORY CYTOKINES AND REDOX HOMEOSTASIS

Sexual Dimorphism in Lipid Metabolism and Gut Microbiota in Mice Fed a High-Fat Diet

Sex Differences Affect the NRF2 Signaling Pathway in the Early Phase of Liver Steatosis: A High-Fat-Diet-Fed Rat Model Supplemented with Liquid Fructose

Disruption of gut barrier integrity and host–microbiome interactions underlie MASLD severity in patients with type-2 diabetes mellitus

Alterations of the duodenal mucosal microbiome in patients with metabolic dysfunction-associated steatotic liver disease

Gut Microbiota and Metabolic Dysfunction-Associated Steatotic Liver Disease

Sex-specific effects of gut microbiome on shaping bile acid metabolism

Alteration of Gut Microbiota Composition in the Progression of Liver Damage in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Sex-specific effects of PNPLA3 I148M

Sex-specific Association Between the Gut Microbiome and High-Fat Diet-Induced Metabolic Disorders in Mice

Metabolic-Dysfunction Associated Liver Disease Progresses Independent of Weight in a Rodent Model

IDDF2024-ABS-0412 Intestinal NLRP3 Deficiency Aggravates MASLD Mice Via Reduced Butyrate Production

Sex-dependent effects of a high fat diet on metabolic disorders, intestinal barrier function and gut microbiota in mouse

Implications of Microbiota and Immune System in Development and Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease

Sex hormones differently regulate lipid metabolism genes in primary human hepatocytes